CSTL vs. HRMY
CSTL (Castle Biosciences, Inc.) and HRMY (Harmony Biosciences Holdings, Inc.) are both stocks. Both are in the Healthcare sector — CSTL in Diagnostics & Research, HRMY in Biotechnology. Over the past 5 years, CSTL returned -20.27%/yr vs -0.67%/yr for HRMY. At a 0.26 correlation, their price movements are largely independent.
Performance
CSTL vs. HRMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CSTL achieves a -47.58% return, which is significantly lower than HRMY's -14.22% return.
CSTL
- 1D
- 3.45%
- 1M
- -20.10%
- YTD
- -47.58%
- 6M
- -48.26%
- 1Y
- 22.02%
- 3Y*
- -3.56%
- 5Y*
- -20.27%
- 10Y*
- —
HRMY
- 1D
- 3.85%
- 1M
- -1.50%
- YTD
- -14.22%
- 6M
- -13.24%
- 1Y
- -9.09%
- 3Y*
- -3.02%
- 5Y*
- -0.67%
- 10Y*
- —
CSTL vs. HRMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
CSTL Castle Biosciences, Inc. | -47.58% | 45.97% | 23.49% | -8.33% | -45.09% | -36.16% | 46.65% |
HRMY Harmony Biosciences Holdings, Inc. | -14.22% | 8.75% | 6.53% | -41.38% | 29.22% | 17.95% | -2.32% |
Correlation
The correlation between CSTL and HRMY is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Aug 20, 2020 | 0.26 |
Fundamentals
CSTL:
$609.44M
HRMY:
$1.89B
CSTL:
-$0.44
HRMY:
$2.48
CSTL:
1.77
HRMY:
2.09
CSTL:
1.32
HRMY:
2.07
CSTL:
$339.92M
HRMY:
$899.11M
CSTL:
$164.74M
HRMY:
$688.25M
CSTL:
$9.62M
HRMY:
$221.74M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CSTL vs. HRMY — Risk / Return Rank
CSTL
HRMY
CSTL vs. HRMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Castle Biosciences, Inc. (CSTL) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CSTL | HRMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.57 | ||
| Sortino ratioReturn per unit of downside risk | +1.01 | ||
| Omega ratioGain probability vs. loss probability | 1.14 | 1.00 | +0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.38 | -0.26 | +0.65 |
| Martin ratioReturn relative to average drawdown | 0.88 | -0.49 | +1.37 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CSTL | HRMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.35 | -0.22 | +0.57 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.27 | -0.01 | -0.26 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.01 | -0.05 | +0.04 |
Drawdowns
CSTL vs. HRMY - Drawdown Comparison
The maximum CSTL drawdown since its inception was -88.02%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for CSTL and HRMY.
Loading charts...
Drawdown Indicators
| CSTL | HRMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -88.02% | -68.48% | -19.54% |
Max Drawdown (1Y)Largest decline over 1 year | -57.83% | -34.49% | -23.34% |
Max Drawdown (3Y)Largest decline over 3 years | -57.83% | -50.81% | -7.02% |
Max Drawdown (5Y)Largest decline over 5 years | -84.97% | -68.48% | -16.49% |
Current DrawdownCurrent decline from peak | -79.05% | -47.30% | -31.75% |
Average DrawdownAverage peak-to-trough decline | -54.66% | -35.20% | -19.46% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.98% | 18.69% | +6.29% |
Volatility
CSTL vs. HRMY - Volatility Comparison
Castle Biosciences, Inc. (CSTL) has a higher volatility of 30.06% compared to Harmony Biosciences Holdings, Inc. (HRMY) at 10.05%. This indicates that CSTL's price experiences larger fluctuations and is considered to be riskier than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CSTL | HRMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 30.06% | 10.05% | +20.01% |
Volatility (6M)Calculated over the trailing 6-month period | 41.23% | 30.17% | +11.06% |
Volatility (1Y)Calculated over the trailing 1-year period | 63.45% | 41.40% | +22.05% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 74.24% | 50.04% | +24.20% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 74.36% | 52.40% | +21.96% |
Dividends
CSTL vs. HRMY - Dividend Comparison
Neither CSTL nor HRMY has paid dividends to shareholders.
Financials
CSTL vs. HRMY - Financials Comparison
This section allows you to compare key financial metrics between Castle Biosciences, Inc. and Harmony Biosciences Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CSTL vs. HRMY - Profitability Comparison
CSTL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Castle Biosciences, Inc. reported a gross profit of 0.00 and revenue of 83.68M. Therefore, the gross margin over that period was 0.0%.
HRMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 170.88M and revenue of 215.39M. Therefore, the gross margin over that period was 79.3%.
CSTL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Castle Biosciences, Inc. reported an operating income of 0.00 and revenue of 83.68M, resulting in an operating margin of 0.0%.
HRMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 37.29M and revenue of 215.39M, resulting in an operating margin of 17.3%.
CSTL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Castle Biosciences, Inc. reported a net income of -14.52M and revenue of 83.68M, resulting in a net margin of -17.4%.
HRMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a net income of 32.49M and revenue of 215.39M, resulting in a net margin of 15.1%.
Frequently Asked Questions
CSTL and HRMY have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CSTL has higher volatility (30.06%) compared to HRMY (10.05%). In terms of maximum drawdown, CSTL dropped -88.02% vs HRMY's -68.48%.
CSTL currently has the higher Sharpe Ratio (0.35 vs -0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CSTL and HRMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer